GLP 3 (RT) 10 & 30mg
Retatrutide (GLP-3) is an investigational synthetic peptide and first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. Also known as LY3437943, it is an acylated peptide studied for its effects on metabolic signaling, glucose regulation, energy balance, lipid metabolism, and body-weight regulation. Current research includes metabolic, endocrinology, obesity, diabetes, and cardiometabolic research.
Certificate of Analysis
Compound information
What is GLP-3 (RT)?
The next step beyond single- and dual-receptor peptides: one molecule that activates three metabolic receptors at once. Adding glucagon-receptor signaling to the GLP-1 and GIP pair, it gives researchers a single tool for studying how all three incretin and glucagon pathways interact.
GLP-3 (RT) structure
Stability information
Product overview
A first-in-class triple receptor agonist supplied for laboratory evaluation at a ≥99% HPLC analytical standard.
Technical overview
Retatrutide or GLP-3 (RT) is a 39-amino-acid peptide built on a glucagon-based scaffold and modified so that a single molecule activates the GLP-1, GIP, and glucagon receptors simultaneously. Non-coded residues at positions 2, 13, and 20 support stability and receptor balance, while a C20 fatty diacid chain enables albumin binding for a longer half-life.
It is made by solid-phase synthesis and preparative purification, then released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
Researchers use Retatrutide to probe how glucagon-receptor activity layers onto incretin signaling that GLP-1 (Sema) and GLP-2 (Tirz) cannot reach. Typical work spans cAMP reporter assays of GCGR, GIPR, and GLP-1R in HEK293 cells, hepatic lipid metabolism and thermogenesis models, and rodent studies measuring energy expenditure alongside food intake.
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
The third target is the glucagon receptor. Adding it to GLP-1 and GIP activation lets a single molecule influence appetite, insulin release, and, through glucagon signaling, hepatic fat metabolism and energy expenditure. That combination is what researchers use GLP-3 (RT) to study, since no dual agonist reaches the glucagon pathway.
Kylo GLP-3 (RT) is supplied at ≥99% purity by HPLC, with identity confirmed through LC-MS. Each lot clears independent third-party testing before it is released, and the corresponding certificate is published against the lot number printed on the vial.
GLP-3 (RT) is registered under CAS number 2381089-83-2 and the development code LY3437943. It carries the molecular formula C221H342N46O68, a molecular weight of roughly 4731.33 g/mol, and a 39-amino-acid chain.
Hold the lyophilized powder at −20 °C, sealed away from light and moisture, with −80 °C preferred for longer storage. The peptide is hygroscopic, so keep its time in open air short. After reconstitution, refrigerate at 2 to 8 °C and use within a validated stability window.
No. Kylo GLP-3 (RT) is intended solely for in vitro laboratory research. It is not formulated or labeled for humans or animals, and unlike GLP-1 (Sema) or GLP-2 (Tirz), it has no approved brand-name product, since it remains investigational.
Retatrutide is an investigational Eli Lilly compound still in clinical trials, and it has not received FDA approval for any use. The material sold here is research-grade, supplied for laboratory work only. Kylo is a chemical supplier, not a compounding pharmacy under section 503A or 503B.
Backed By A Lot-Matched COA
Every GLP-3 (RT) order is tied to a certificate of analysis matched to the exact lot in your vial.
Shop catalog →
